A cikin 'yan shekarun nan, tasirin masu hana kariya daga bincike kan cutar lymphoma na Hodgkin (HL) abin birgewa ne, amma har yanzu ana bukatar shawo kan cutar sosai. Shugaban Kamfanin Mayo Clinic na Lymphoma Group Ansell sai ..
Masu bincike a Jami'ar California, San Francisco da Asibitin Bincike na Yara na St. Jude a Tennessee sun warware sirrin likitancin shekaru da yawa da suka gabata, kuma sun gano wasu canje-canje na kwayar halitta da ka iya haifar da cutar ..
FDA ta ba da babbar nasara ta quizartinib magani mai nasara. Quizartinib shine mai hana FLT3 a ƙarƙashin bincike don kula da tsofaffin marasa lafiya tare da koma baya / ƙyamar FLT3-ITD myeloi ..
Hukumar Abinci da Magunguna ta Amurka ta amince da Venetoclax (Venclexta) hade da rituximab (VenR) don kula da marasa lafiya masu fama da cutar sankarar bargo ta lymphocytic (CLL) dangane da ƙaramar cutar saura (MRD) data lokaci guda ..
Dangane da gwaji na asibiti da yawa wanda masu bincike suka gudanar a Makarantar Koyon Magunguna ta Jami'ar Stanford, wani sabon nau'in maganin rigakafi da alama yana da lafiya ga marasa lafiya da ke fama da cutar kansa da ake kira lymphoma ba ta Hodgkin ba.
Dangane da sakamakon kashi na biyu na binciken, haduwar magani na kimoterapi mai kyau azacitidine da kuma mai hana kariya kariya na nivolumab (nivolumab) ya nuna cewa yawan martani da sake dawowa ..
On November 28, FDA approved the first rituximab (Rituxan, rituximab) biosimilar, Truxima (rituximab-abbs, Celltrion Inc.) for non-Hodgkin's lymphoma (NHL). Rituximab is a monoclonal antibody against CD20. It is widely used..
FDA ta Amurka ta amince da gilteritinib (Xospata) don kula da tsofaffi marasa lafiya tare da FLT3 maye gurbi-tabbatacce koma baya ko refractory m myeloid cutar sankarar bargo (AML). Lokacin amfani da gil..
Sakamakon gwajin gwaji na asibiti da yawa na kashi III ya nuna cewa idan tsofaffi marasa lafiya da cutar sankarar lymphocytic na yau da kullun (CLL) ana bi da su tare da sabon magani ibrutinib da aka yi niyya idan aka kwatanta da na baya.
Venetoclax (Venclexta) da rituximab (Rituxan) ana amfani da su a hade tare da relapsed / refractory na kullum lymphocytic cutar sankarar bargo (CLL), haifar da wani babban adadin da ba a iya gano kadan saura cuta (uMRD), wanda shi ne kamar yadda.